N/A Completed N=71

Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment

Late Onset Alzheimer

Source: ClinicalTrials.gov NCT02007291 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2018

Primary outcomePrimary: Cognitive Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease — 19; 11.3; 18.9; 11.5 units on a scale

Summary

Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly. Pharmacologic treatment of AD is based on cholinesterase inhibitors (ChEI) and memantine, leading to modest clinical benefits both in the short and long-term. However, clinical response is heterogeneous and needs further investigation. Objective: To investigate the rate of response to ChEI in AD after three months of treatment. Methods: Patients with mild or moderate dementia due to probable AD or to AD associated with cerebrovascular disease were included in the study.

Outcome Measures

Outcome	Result	p-value
PRIMARY Cognitive Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease	19; 11.3; 18.9; 11.5	—
SECONDARY Independence for Daily Activities Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease	14.9; 26.9; 16.2; 27.1	—

Eligibility Criteria

Inclusion Criteria

Patients fulfilling the National Institute on Aging and the Alzheimer's Association diagnostic criteria of probable AD dementia or the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) diagnostic criteria of AD with cerebrovascular disease (AD + CVD)
Patients presenting mild or moderate dementia according to the Clinical Dementia Rating (CDR), i.e., CDR 1 or 2, respectively

Exclusion Criteria

Patients treated with ChEI or memantine before study entry
Patients diagnosed with frontotemporal dementia, dementia with Lewy bodies or vascular dementia,
Patients with CDR 3
Illiterate patients
Patients with different comorbidities, with signs of clinical decompensation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02007291). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.